Sir Charles Gairdner Hospital, Australia.
Mult Scler. 2013 Sep;19(10):1371-80. doi: 10.1177/1352458512471092. Epub 2013 Jan 16.
Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.
明确炎症性脱髓鞘疾病（多发性硬化症（MS）和视神经脊髓炎（NMO））的诊断可能需要时间，但早期治疗为最大限度地提高患者的治疗效果提供了机会。本报告的目的是为炎症性脱髓鞘疾病患者在明确诊断之前提供指导，以促进早期治疗决策。神经病学专家回顾了现有的文献和临床证据。制定了一种治疗决策途径，定义了一线 MS 疾病修正治疗（a）不太可能有效的患者，（b）可能有效但需要仔细监测的患者，以及（c）可能受益的患者。该算法旨在确保患者，特别是亚洲患者，在炎症性脱髓鞘疾病早期接受适当的治疗。
